DDD earnings analysis
What we found in DDD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 revenue was essentially flat year over year at $94.579 million, down $0.259 million (0.3%), and declined from $95.538 million in Q1 2026. Gross margin fell to 36.4% from 38.1% a year earlier and operating margin was negative 11.3%, although the operating loss improved to $10.645 million from $15.350 million through substantial R&D and restructuring-related savings. GAAP diluted EPS was a $0.09 loss, versus a $0.03 loss in Q1 and $0.57 profit in Q2 2025, with the prior-year result benefiting from a $125.681 million disposition gain. Liquidity improved after a $53.8 million equity raise, but cash generation remains negative and the company retains meaningful covenant, debt, and internal-control risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Healthcare growth offset industrial weakness
- Healthcare Solutions revenue rose $3.076 million, or 6.8%, to $48.096 million, led by higher medical-technology printer volume, personalized healthcare services, and favorable price/mix.
- Cost actions materially narrowed operating loss
- Operating loss narrowed $4.705 million year over year to $10.645 million. R&D expense fell $7.389 million (42.6%) to $9.972 million, reflecting restructuring, divestitures, and cost actions.
- Operating cash burn improved sharply
- Six-month operating cash outflow improved $45.524 million year over year to $14.106 million, driven primarily by improved business performance from the 2025 Restructuring Plan and other savings actions.
- Equity raise strengthened cash balance
- Cash and equivalents increased $32.316 million, or 33.8%, from year-end to $127.951 million, primarily from a $53.8 million equity raise.
- Receivables and inventory declined
- Working-capital assets improved modestly: receivables declined $3.632 million to $80.174 million and inventories declined $5.649 million to $121.847 million versus December 31, 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Gross margin contracted despite tariff recovery
- Quarterly gross margin fell 170 basis points year over year to 36.4% as cost of sales increased $1.429 million to $60.117 million; management cited unfavorable mix and divestitures, partly offset by a $2.6 million tariff recovery.
- Industrial segment remained under pressure
- Industrial Solutions revenue declined $3.335 million, or 6.7%, to $46.483 million, primarily due to divestitures and unfavorable price/mix. Its gross profit declined $0.510 million to $15.258 million.
- Debt covenant and liquidity risk remain
- The company had $92.0 million of 2030 Notes outstanding and must maintain at least $20.0 million in qualified cash. Management states insufficient future cash generation could trigger non-compliance and make the $92.0 million balance immediately due.
- Material weaknesses remain unremediated
- Management concluded disclosure controls and procedures were not effective as of June 30, 2026 because of material weaknesses previously identified in the 2025 Form 10-K; remediation remains in progress.
- Near-term 2026 note maturity
- The filing reports no material changes to risk factors from the 2025 Form 10-K, but the 2026 Notes' $3.9 million principal balance matures November 15, 2026 and total debt principal was $96.0 million at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.09
- Gross margin
- 36.4%
- Operating margin
- -11.3%
- Segment
- Healthcare Solutions: $48.096 million revenue, up $3.076 million (6.8%) year over year; segment gross profit was $19.204 million, down $1.178 million.
- Segment
- Industrial Solutions: $46.483 million revenue, down $3.335 million (6.7%) year over year; segment gross profit was $15.258 million, down $0.510 million.
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS guidance. MD&A states management expects cash flow from operations, cash and equivalents, and other liquidity sources to be sufficient for anticipated requirements over the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- 3D Systems reported a revenue decrease of 19.2% year-over-year, generating $95.5 million in Q1 2026. The gross margin improved to 35.9%, up from 34.6% a year prior, but the operating margin remains negative. In the…
- 10-K · March 9, 2026
- 3D Systems reported a fourth-quarter revenue beat of $106,275,000 (8.22% above the $98,199,750 estimate) and notes a solutions-oriented strategy focused on Healthcare and Industrial verticals. Despite the revenue beat…
- 10-Q · November 4, 2025
- 3D Systems reported Q3 2025 revenue of $91.249 million, a decline of 19.4% year-over-year from $112.940 million. The net loss for the quarter was $18.053 million, leading to a diluted EPS of -$0.14. Operating margins…
- 10-Q · August 11, 2025
- 3D Systems reported Q2 revenue of $94.838M, down from $113.252M a year ago, while GAAP net income swung to $104.436M (diluted EPS $0.57) driven primarily by a pre-tax gain on the April 1, 2025 sale of Geomagic of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DDD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever